(lp0
S'Madrigal Pharmaceuticals Reports 2016 Fourth Quarter and Year-End Financial ... GlobeNewswire  - Apr 3, 2017 CONSHOHOCKEN, Pa., April 03, 2017  -- Madrigal Pharmaceuticals, Inc.  today announced its fourth quarter and year-end 2016 financial results.MADRIGAL PHARMACEUTICALS,INC.  Files An 8-K Results of Operations ... - Market Exclusive'
p1
aS'15.75 MarketWatch - Jul 25, 2016 Madrigal Pharmaceuticals Inc. Madrigal Pharmaceuticals, Inc. develops novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis .'
p2
aS'Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading ... GlobeNewswire  - Jul 22, 2016 FORT WASHINGTON, Pa., July 22, 2016  -- Madrigal Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the&nbsp;...'
p3
aS"Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License ... GlobeNewswire  - Sep 19, 2016 CONSHOHOCKEN, Pa. and WATERTOWN, Mass., Sept. 19, 2016  -- Madrigal Pharmaceuticals, Inc.  and Tarveda Therapeutics, Inc. today announced an exclusive worldwide license agreement providing for the&nbsp;...With $163M Deal, Tarveda Revives Synta Pharma's Cancer Drug Work - XconomyTarveda to Develop Oncology Treatments Based on Madrigal's HSP90 Drug ... - Genetic Engineering & Biotechnology News "
p4
aS'Price Alert: Madrigal Pharmaceuticals Inc  Stock Nears Resistance ... CML News - Apr 12, 2017 Price Alert: Madrigal Pharmaceuticals Inc  has now crossed into technical strength -- watch the technical oscillators for momentum gaps.'
p5
aS'Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL ... GlobeNewswire  - Oct 20, 2016 CONSHOHOCKEN, Pa., Oct. 20, 2016  -- Madrigal Pharmaceuticals, Inc.  today announced that the first patient has been dosed in its Phase 2 study of MGL-3196 for the treatment of non-alcoholic steatohepatitis .'
p6
aS'Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals Zacks.com - Apr 15, 2016 This all-stock transaction will lead to the formation of a new company named Madrigal Pharmaceuticals, which will focus on the development of novel small-molecule drugs addressing major unmet needs related to cardiovascular-metabolic diseases and&nbsp;...Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular ... - Business Wire Synta Pharma and Madrigal Pharma to merge in all-stock deal - Seeking Alpha'
p7
aS'Synta - Madrigal Merger: Is There A Potential Value Play Here? Seeking Alpha - Aug 23, 2016 On April 13, 2016 Synta and Madrigal Pharmaceuticals  entered into an arrangement and plan of merger pursuant to which Saffron Merger Sub Inc., a wholly owned subsidiary of Synta, will merge into MDGL, with Madrigal surviving as the&nbsp;...'
p8
aS'Madrigal Pharmaceuticals Inc  Stock Technicals Hit Weakness CML News - Feb 23, 2017 This is a technical analysis stock rating for Madrigal Pharmaceuticals Inc  . The company has a two bull technical rating which indicates some weakness.'
p9
aS'Synta Pharmaceuticals Has Great Product But No Money Seeking Alpha  - Mar 18, 2015 There is tremendous support among the cancer community for ganetespib, with third-party groups sponsoring most of its advanced trials.'
p10
a.